EU Grants EUR 6M to the Clinical Development of Athera Biotechnologies's Cardiovascular Disease Antibody Therapy

Published: Jun 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STOCKHOLM, SWEDEN – June 17, 2013. Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof -of-concept will be co-funded by the European Union’s Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.

Help employers find you! Check out all the jobs and post your resume.

Back to news